Short answer
Assembly Biosciences Inc (ASMB) filed an 8-K current report with the SEC on August 14, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Assembly Biosciences announced financial results for the quarter ended June 30, 2026.
Assembly Biosciences Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Assembly Biosciences announced financial results for the quarter ended June 30, 2026
- Exhibit 99.1 contains the substantive financial results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $13.4M, up from $9.6M, including a $5.1M cumulative catch-up from Gilead collaboration estimates
- Net loss narrowed to $3.9M, or $0.20 per share, from $10.2M, or $1.33, helped by collaboration revenue and interest income
- Cash, equivalents and marketable securities reached $320.4M, with runway projected into 2029 including Gilead’s $75M Q4 payment
- $115M gross financing strengthens funding through ABI-6250 Phase 2 studies in HDV and cholestatic liver diseases
- GS-1179 Phase 2 expected by year-end 2026, with opt-in decision on 40% U.S. cost-profit share also due by year-end
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Assembly Biosciences Inc 8-K filings
Get the next ASMB 8-K as it lands
Follow ASMB for push alerts, or ask the research agent what this filing means.